6th International Immunoglobulin Symposium: Poster presentations
暂无分享,去创建一个
E Fernandez-Cruz | S V Kaveri | H-H Peter | A Durandy | N Cantoni | I Quinti | R Sorensen | J B Bussel | M G Danieli | A Winkelmann | J Bayry | F Käsermann | P Späth | M Helbert | A Salama | I N van Schaik | N Yuki | A. Durandy | S. Kaveri | J. Bussel | N. Yuki | R. Sorensen | A. Winkelmann | F. Käsermann | H. Peter | P. Späth | M. Danieli | I. Quinti | E. Fernandez-cruz | M. Helbert | I. Van Schaik | N. Cantoni | A. Salama | J. Bayry
[1] F. Bonilla. Intravenous immunoglobulin: adverse reactions and management. , 2008, The Journal of allergy and clinical immunology.
[2] P. Modrich,et al. Endonucleolytic Function of MutLα in Human Mismatch Repair , 2006, Cell.
[3] S. Kaveri,et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. , 2003, Blood.
[4] A. Fischer,et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination , 2008, The Journal of experimental medicine.
[5] J. Kelton,et al. Diagnosis and management of neonatal alloimmune thrombocytopenia. , 2008, Transfusion medicine reviews.
[6] J. Huggins,et al. Use of intravenous immunoglobulin G (IVIG). , 2006, Best practice & research. Clinical haematology.
[7] M. Hutchinson,et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.
[8] M. Ballow. Safety of IGIV therapy and infusion-related adverse events , 2007, Immunologic research.
[9] P. Modrich,et al. Endonucleolytic function of MutLalpha in human mismatch repair. , 2006, Cell.
[10] V. Wahn,et al. Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success , 2005, International Archives of Allergy and Immunology.
[11] R. Hughes,et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy * , 2006, European journal of neurology.
[12] M. Berger. Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency , 2008, Immunology and Allergy Clinics of North America.
[13] A. Gabrielli,et al. [Intravenous immunoglobulin treatment in autoimmune diseases]. , 2007, Recenti progressi in medicina.
[14] J. Dambrosia,et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.
[15] H. Isliker,et al. Intravenous Administration of Human γ‐Globulin * , 1962 .
[16] S. Kaveri,et al. DC-SIGN and α2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells , 2009, Proceedings of the National Academy of Sciences.
[17] R. Berkowitz,et al. Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia , 2006, Obstetrics and gynecology.
[18] A. Fischer,et al. Human uracil–DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination , 2003, Nature Immunology.
[19] Christian Confavreux,et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. , 2004, Brain : a journal of neurology.
[20] M. Turner,et al. An update on the assessment and management of the risk of transmission of variant Creutzfeldt‐Jakob disease by blood and plasma products , 2009, British journal of haematology.
[21] M. Sturzenegger,et al. Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.
[22] M. Hutchinson,et al. Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .
[23] R. Berkowitz,et al. Alloimmune thrombocytopenia: state of the art 2006. , 2006, American journal of obstetrics and gynecology.